We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems
Read MoreHide Full Article
Key Takeaways
GEHC adds Vivid Explorer, Vivid Advanced and Vivid Focus to expand cardiovascular imaging options.
AI-enabled tools and cSound imaging aim to simplify cardiac measurements and enhance visualization.
The new Vivid systems have CE Mark approval, while FDA 510(k) clearance remains pending.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings. The systems are being showcased at the European Society of Cardiology Congress 2026 in Munich, Germany.
Per management, the company developed the new Vivid systems after working closely with care teams across echo labs, cardiology practices and interventional settings. Building Vivid Explorer, Vivid Advanced and Vivid Focus on the same technology foundation as Vivid Pioneer enables GE HealthCare to address the distinct needs of each setting while delivering a consistent Vivid imaging and user experience.
GEHC Stock Trend Following the News
GEHC stock has lost 1% since the announcement on Friday. Year to date, the stock has fallen 12.6% compared with the industry’s 15.6% decline. However, the S&P 500 has risen 12.2% in the same timeframe.
The expansion of the Vivid portfolio could strengthen GE HealthCare’s position in the cardiovascular ultrasound market by addressing a broader range of clinical environments. The introduction of AI-enabled workflow tools, advanced imaging capabilities and a common technology platform may support adoption among hospitals, cardiology practices and echo labs, creating additional growth opportunities for GEHC in medical imaging.
GEHC currently has a market capitalization of $32.40 billion.
Image Source: Zacks Investment Research
More on the Vivid Portfolio
Vivid Explorer is designed for high-volume echo labs and routine interventional procedures, offering 4D, multi-plane and 2D imaging across transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) and intracardiac echocardiography (ICE), along with AI and automation features.
Vivid Advanced targets mid-size hospitals and cardiology practices requiring comprehensive cardiac imaging. The system supports vascular, abdominal and soft-tissue examinations.
Vivid Focus brings cSound imaging technology to everyday cardiac imaging and includes the new 4Sc-RS probe, AI-enabled workflow tools and support for vascular, abdominal and soft-tissue exams. The portfolio also includes Vivid iq, a portable ultrasound system offering advanced cardiovascular, abdominal and musculoskeletal imaging capabilities.
All three new systems use cSound, a software-based imaging architecture designed to enhance contrast, resolution and tissue visualization. AI-enabled tools, including AI Auto Measure 2D, Easy AutoEF, Easy AFI LV and AI Cardiac Auto Doppler, are designed to reduce manual steps and simplify cardiac measurements.
GE HealthCare also introduced EchoPAC Software Only v211, enabling clinicians to review, analyze and quantify studies remotely or on-site using workflows consistent with the Vivid systems. The new Vivid systems and EchoPAC Software Only v211 have received CE Mark, while FDA 510(k) clearance remains pending.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global cardiovascular ultrasound market is predicted to be valued at $3.40 billion in 2026 and is expected to witness a CAGR of 4.7% through 2033.
Factors like the rising prevalence of cardiovascular diseases, advancements in ultrasound imaging technologies and growing demand for non-invasive diagnostic procedures are boosting the market’s growth.
Other News
GE HealthCare recently introduced the LOGIQ e family, including LOGIQ e Xi and LOGIQ e Si, compact laptop ultrasound systems designed for fast, confident imaging across care settings. The systems combine console-level performance, portability, AI-powered features and workflow tools for flexible point-of-care use.
GE HealthCare also launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio. The FDA-cleared and CE-marked solutions support supplemental screening for women with dense breasts, standardized 3D ultrasound acquisition, remote reading and streamlined exam review across multi-site networks.
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings. The systems are being showcased at the European Society of Cardiology Congress 2026 in Munich, Germany.
Per management, the company developed the new Vivid systems after working closely with care teams across echo labs, cardiology practices and interventional settings. Building Vivid Explorer, Vivid Advanced and Vivid Focus on the same technology foundation as Vivid Pioneer enables GE HealthCare to address the distinct needs of each setting while delivering a consistent Vivid imaging and user experience.
GEHC Stock Trend Following the News
GEHC stock has lost 1% since the announcement on Friday. Year to date, the stock has fallen 12.6% compared with the industry’s 15.6% decline. However, the S&P 500 has risen 12.2% in the same timeframe.
The expansion of the Vivid portfolio could strengthen GE HealthCare’s position in the cardiovascular ultrasound market by addressing a broader range of clinical environments. The introduction of AI-enabled workflow tools, advanced imaging capabilities and a common technology platform may support adoption among hospitals, cardiology practices and echo labs, creating additional growth opportunities for GEHC in medical imaging.
GEHC currently has a market capitalization of $32.40 billion.
Image Source: Zacks Investment Research
More on the Vivid Portfolio
Vivid Explorer is designed for high-volume echo labs and routine interventional procedures, offering 4D, multi-plane and 2D imaging across transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) and intracardiac echocardiography (ICE), along with AI and automation features.
Vivid Advanced targets mid-size hospitals and cardiology practices requiring comprehensive cardiac imaging. The system supports vascular, abdominal and soft-tissue examinations.
Vivid Focus brings cSound imaging technology to everyday cardiac imaging and includes the new 4Sc-RS probe, AI-enabled workflow tools and support for vascular, abdominal and soft-tissue exams. The portfolio also includes Vivid iq, a portable ultrasound system offering advanced cardiovascular, abdominal and musculoskeletal imaging capabilities.
All three new systems use cSound, a software-based imaging architecture designed to enhance contrast, resolution and tissue visualization. AI-enabled tools, including AI Auto Measure 2D, Easy AutoEF, Easy AFI LV and AI Cardiac Auto Doppler, are designed to reduce manual steps and simplify cardiac measurements.
GE HealthCare also introduced EchoPAC Software Only v211, enabling clinicians to review, analyze and quantify studies remotely or on-site using workflows consistent with the Vivid systems. The new Vivid systems and EchoPAC Software Only v211 have received CE Mark, while FDA 510(k) clearance remains pending.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global cardiovascular ultrasound market is predicted to be valued at $3.40 billion in 2026 and is expected to witness a CAGR of 4.7% through 2033.
Factors like the rising prevalence of cardiovascular diseases, advancements in ultrasound imaging technologies and growing demand for non-invasive diagnostic procedures are boosting the market’s growth.
Other News
GE HealthCare recently introduced the LOGIQ e family, including LOGIQ e Xi and LOGIQ e Si, compact laptop ultrasound systems designed for fast, confident imaging across care settings. The systems combine console-level performance, portability, AI-powered features and workflow tools for flexible point-of-care use.
GE HealthCare also launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio. The FDA-cleared and CE-marked solutions support supplemental screening for women with dense breasts, standardized 3D ultrasound acquisition, remote reading and streamlined exam review across multi-site networks.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.